A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and ...
Bristol Myers Squibb (BMS) announced four-year follow-up results from the phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy ...
The appraisal committee considered evidence submitted by Bristol Myers Squibb, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers ...
Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer PRINCETON, ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the first presentation of results from the Phase 3 CheckMate -9LA trial, which demonstrated a statistically ...
Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include ...
No new safety signals were observed with Opdivo plus Yervoy with two cycles of chemotherapy with extended follow-up in the CheckMate -9LA trial. These data will be featured in a late-breaking poster ...
Bristol-Myers Squibb Company announced that CheckMate -9LA, a pivotal phase 3 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) given concomitantly with two cycles of chemotherapy ...
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #ASCO--Bristol Myers Squibb (NYSE: BMY) today announced four-year follow-up results from the Phase 3 CheckMate -9LA trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback